Immunotherapy rechallenge in metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials
In summary, PD-1/PD-L1 inhibitor rechallenge with a VEGF TKI in mRCC does not improve survival outcomes and should not be used in patients with prior progression to ICI. Understanding both intrinsic and acquired resistance mechanisms to ICI therapy is crucial for developing effective initial and sequential immunotherapy strategies in RCC.
Authors
- Hatice Bölek (ORCID: https://orcid.org/0000-0001-8659-7327)
- R. McKay
- Bradley A. McGregor (ORCID: https://orcid.org/0000-0002-8298-0289)
- Satı Coskun Yazgan
- Emre Yekedüz
- Sumanta K Pal
- Toni K Choueiri
Institutions
- Ankara University (TR)
- University of California San Diego (US)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1093/oncolo/oyaf426
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52